新綸科技(002341.SZ):2021年度擬向銀行及金融機構等申請不超40億元綜合授信額度
格隆匯 11 月 13日丨新綸科技(002341.SZ)公佈,公司第五屆董事會第十八次會議決議,審議通過了《關於預計公司2021年度擬向銀行及金融機構等申請綜合授信額度的議案》;
董事會同意公司及子公司2021年度擬向銀行及金融機構等申請不超過人民幣40億元的綜合授信額度,授信額度有效期限為自2021年1月1日至2021年12月31日,授信期限內,授信額度可循環使用。
董事會授權公司副董事長或總裁代表公司簽署上述授信額度內與授信(包括但不限於授信、借款、抵押、融資等)有關的合同、協議、憑證等各項法律文件,並辦理相關手續。
該議案尚需提交公司2020年第四次臨時股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.